Form 4 for KURA Kura Oncology, Inc.
Accepted 2023-01-31 00:00:00 ET · period of report 2023-01-27 · accession 0001209191-23-005746 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-01-31 | 2023-01-27 | KURA | DOYLE THOMAS JAMES | SVP, Fin, Accounting | S - Sale | $13.89 | -1,548 | 17.7K | -8% | -$21.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-27 | S | D | 866 | $13.89 | 16,841 | D | — | — | (F3) Sell-to cover for taxes associated with the vesting of RSUs received by the Reporting Person dated 2/7/22. |
| 2 | Common | Common Stock | 2023-01-27 | S | D | 682 | $13.89 | 17,707 | D | — | — | (F1) Sell-to cover for taxes associated with the vesting of RSUs received by the Reporting Person dated 1/26/22. (F2) Includes 1,806 shares acquired on May 17, 2022 and 1,583 shares acquired on November 17, 2022 pursuant to the Issuer's Employee Stock Purchase Plan. |